There are four distinct brainstem monitoring markets for the TMU system.  These are (1) Comatose Monitoring and Brainstem Death Diagnosis, (2) Brain Monitoring during General Anesthesia, (3) Neuro-Disease Management, and (4) Monitoring Sleep Patterns.  

EyeTect, LLC will focus on conducting clinical trials to prove the economic and clinical outcomes within the first of the above markets:  Comatose Monitoring and Brainstem Death Diagnosis.  Click on the links to the left to learn more about these areas as well as Market Statistics.

Market Need for OMT in Coma and Brainstem Death 
Clinical monitoring of the neuro-disabled patient during hospitalization has not significantly changed in 15 years.  While technology advances have been developed across the hospital and particularly for the cardiac disabled patient where routine continuous monitoring is readily available utilizing the electrocardiograph (EKG), no such routine ability yet exists in the Neuro Intensive Care Unit (the “NICU”).

OMT can bring to the NICU what the EKG provides to the Cardiac Unit:  a direct, continuous measure of the electrical activity of the organ of most interest to the clinician – the brainstem.